Want to see ALUR full AI Analyst Report?
Allurion Technologies (ALUR) AI Stock Analysis
Allurion Technologies
(Other OTC:ALUR)
The score is driven primarily by very weak financial performance (shrinking revenue, extreme losses, negative equity, and ongoing cash burn) and strongly bearish technicals (deeply oversold readings and price far below key moving averages). Valuation cannot be supported with the provided P/E and missing dividend yield, offering limited offset to the fundamental and technical weakness.
Allurion Technologies (ALUR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $21.01K
- Dividend Yield
- ―
- Average Volume (3M)
- 3,291
- Price to Earnings (P/E)
- 0.0
- Beta (1Y)
- 3.17
- Revenue Growth
- -55.49%
- EPS Growth
- 21.55%
- Country
- US
- Employees
- 40
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurion B...
How the Company Makes Money
Allurion primarily makes money by selling its weight-loss solution to healthcare providers and/or clinics that deliver the program to patients. Revenue is generated from the commercial sale of the Allurion Balloon (a single-use device for each treate...
Allurion Technologies Financial Statement Overview
Summary
Financials are very weak: TTM revenue fell to $12.6M (~17% decline) continuing a steep multi-year contraction, while profitability is deeply negative (TTM net margin ~-265%) with large operating losses. The balance sheet is highly strained with negative equity (~-$77.9M) and debt (~$29.4M) exceeding the asset base (~$14.0M), and cash burn remains heavy (TTM OCF/FCF about -$22.7M), implying elevated liquidity and dilution/recapitalization risk.
Income Statement
18Very NegativeBalance Sheet
12Very NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.60M | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Gross Profit | 6.64M | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| EBITDA | -39.46M | -27.70M | -22.17M | -69.03M | -32.28M | -8.01M |
| Net Income | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
Balance Sheet | ||||||
| Total Assets | 13.99M | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total Debt | 29.45M | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Total Liabilities | 91.91M | 92.96M | 110.79M | 142.20M | 83.68M | 73.64M |
| Stockholders Equity | -77.91M | -77.19M | -77.98M | -70.49M | -32.31M | -34.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.70M | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
| Operating Cash Flow | -22.70M | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Investing Cash Flow | 0 | 0 | -611.00K | -1.61M | -1.55M | -912.00K |
| Financing Cash Flow | 7.34M | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
Allurion Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.48, below the 50-day MA of 1.03, and below the 200-day MA of 8.69, indicating a bearish trend. The MACD of -0.30 indicates Positive momentum. The RSI at 18.28 is Positive, neither overbought nor oversold. The STOCH value of 1.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 88 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAllurion Technologies Peers Comparison
Overall Rating
SINT51Neutral
XAIR44Neutral
NVNO43Neutral
CODX40Underperform- ALUR39Underperform
IRIX37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| SINT | 51Neutral | $12.85M | -0.31 | -565.55% | ― | -28.53% | 47.55% |
| XAIR | 44Neutral | $3.73M | -0.04 | -462.50% | ― | 60.75% | 71.34% |
| NVNO | 43Neutral | $4.68M | -0.03 | -70.33% | ― | ― | 40.73% |
| CODX | 40Underperform | $3.24M | -0.01 | -210.99% | ― | -9.18% | 33.16% |
| ALUR | 39Underperform | $20.51K | 0.00 | 44.17% | ― | -55.49% | 21.55% |
| IRIX | 37Underperform | $12.50M | -3.50 | -78.94% | ― | 3.68% | 36.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ALUR | Allurion Technologies, Inc. | 0.02 | -27.13 | -99.93% | |
| IRIX | Iridex | 0.71 | -0.36 | -33.55% | |
| SINT | Sintx Technologies | 1.70 | -1.64 | -49.10% | |
| CODX | Co-Diagnostics | 0.37 | -11.76 | -96.98% | |
| XAIR | Beyond Air | 2.24 | -36.76 | -94.26% | |
| NVNO | Envveno Medical Corporation | 6.73 | -18.11 | -72.91% |
Allurion Technologies Corporate Events
Allurion Technologies Restructures Board After Director Resignations
NegativeOn August 17, 2026, Allurion Technologies director Krishna Gupta, a Class I board member, resigned from the board and the Nominating and Corporate Governance Committee, effective the same day. Two days later, on August 19, 2026, Class III director Mi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026